Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The authors assessed the use of herbal medicine by Middle Eastern patients with cancer, as reported by their oncology health care professionals (HCPs). Herbal products identified by the study HCPs were evaluated for potential negative effects. METHODS: Oncology HCPs from 16 Middle Eastern countries received a 17‐item questionnaire asking them to list 5 herbal products in use by their patients with cancer. A literature search (PubMed, Micromedex, AltMedDex, and the Natural Medicine Comprehensive Database) was conducted to identify safety‐related concerns associated with the products listed. RESULTS: A total of 339 HCPs completed the study questionnaire (response rate of 80.3%), identifying 44 herbal and 3 nonherbal nutritional supplements. Safety‐related concerns were associated with 29 products, including herb‐drug interactions with altered pharmacodynamics (15 herbs), direct toxic effects (18 herbs), and increased in vitro response of cancer cells to chemotherapy (7 herbs). CONCLUSIONS: Herbal medicine use, which is prevalent in Middle Eastern countries, has several potentially negative effects that include direct toxic effects, negative interactions with anticancer drugs, and increased chemosensitivity of cancer cells, requiring a reduction in dosedensity. Oncology HCPs working in countries in which herbal medicine use is prevalent need to better understand the implications of this practice. The presence of integrative physicians with training in complementary and traditional medicine can help patients and their HCPs reach an informed decision regarding the safety and effective use of these products. Cancer 2016;122:598–610. © 2015 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer
Banerjee, S., Kaseb, A. O., Wang, Z., Kong, D., Mohammad, M., Padhye, S., Sarkar, F. H., & Mohammad, R. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4235 · Cited by 244 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundRetractedEncyclopedia of common natural ingredients used in food, drugs and cosmetics
(1982) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(82)90080-0 · Cited by 1,025
DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 670
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584 · cited 3×
“7) 6 Camel milk Sudan 2 1 (50) 1 Syria 1 1 (100) 1 Tunisia 3 1 (33.”
BackgroundHerbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom, A., Cox, M. C., Acharya, M. R., & Figg, W. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.182 · Cited by 473 · cited 1×
“As a result, there are those in the medical profession who have issued an across-the-board recommendation to avoid the use of all herbal products during active anticancer treatment.(24) Although this may be prudent, it is a somewhat unrealistic solution for oncology HCPs working in communities in which herbal medicine…”
BackgroundThe effect of garlic supplements on the pharmacokinetics of saquinavir
Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D., & Falloon, J. (2002) · Clinical Infectious Diseases · doi:10.1086/324351 · Cited by 431 · cited 4×
“These were mediated primarily through the cytochrome P450 enzymes, primarily induction of CYP3A4.(37,38) CYP induction can cause a reduction in bioavailability and subsequently the effectiveness of anticancer agents,(39-41) whereas enzyme inhibition can increase the risk of toxicity, such as that observed with etoposi…”
BackgroundInfluentialDisclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies
Robinson, A., & McGrail, M. R. (2004) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2004.09.006 · Cited by 409 · cited 1×
“This allowed us to avoid several patient-based biases, such as a reporting bias resulting from nondisclosure of CTM use to researchers who patients may have believed had a negative attitude regarding nonconventional medical approaches.(101) For this purpose, we asked oncology HCPs to provide a list of herbal products…”
MethodSt John's wort (Hypericum perforatum): drug interactions and clinical outcomes
Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B., & Arlett, P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01683.x · Cited by 380 · cited 4×
“These were mediated primarily through the cytochrome P450 enzymes, primarily induction of CYP3A4.(37,38) CYP induction can cause a reduction in bioavailability and subsequently the effectiveness of anticancer agents,(39-41) whereas enzyme inhibition can increase the risk of toxicity, such as that observed with etoposi…”
BackgroundInfluentialInhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil
Petroni, A., Blasevich, M., Salami, M., Papini, N., Montedoro, G. F., & Galli, C. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)00043-7 · Cited by 363 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundPotential interactions between alternative therapies and warfarin
Heck, A. M., DeWitt, B. A., & Lukes, A. L. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.13.1221 · Cited by 355 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundBordia, A., Verma, S. K., & Srivastava, K. C. (1997) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(97)90587-1 · Cited by 349 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundDavis, E. L., Oh, B., Butow, P. N., Mullan, B. A., & Clarke, S. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0223 · Cited by 346
Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J., Cadenas, E., Louie, S. G., Petasis, N. A., Chen, T. C., & Schönthal, A. H. (2009) · Blood · doi:10.1182/blood-2008-07-171389 · Cited by 289 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundMarchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284 · cited 1×
“Other factors such as the transporter P-glycoprotein have been examined as well.(15) The findings of this research are often contradictory, demonstrating either antagonistic effects,(16) additive effects,(17) synergy,(18) or no interaction whatsoever.”
BackgroundJiang, X., Williams, K. M., Liauw, W. S., Ammit, A. J., Roufogalis, B. D., Duke, C. C., Day, R. O., & McLachlan, A. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02051.x · Cited by 274 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundEstrogen and Progestin Bioactivity of Foods, Herbs, and Spices
Zava, D. T., Dollbaum, C. M., & Blen, M. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44247 · Cited by 261 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundRegulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural Products
Raucy, J. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.533 · Cited by 249 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundHerb–Drug Interactions in Oncology: Focus on Mechanisms of Induction
Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-742 · Cited by 235
Rose, K. D., Croissant, P. D., Parliament, C. F., & Levin, M. B. (1990) · Neurosurgery · doi:10.1227/00006123-199005000-00026 · Cited by 217 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundInteractions of Green Tea Catechins with Organic Anion-Transporting Polypeptides
Roth, M., Timmermann, B. N., & Hagenbuch, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036640 · Cited by 201 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundFlavonoids inhibit platelet function through binding to the thromboxane A2 receptor
GUERRERO, J. A., LOZANO, M. L., CASTILLO, J., BENAVENTE‐GARCÍA, O., VICENTE, V., & RIVERA, J. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01099.x · Cited by 187 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundInhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products
Appiah-Opong, R., Commandeur, J. N. M., van Vugt-Lussenburg, B., & Vermeulen, N. P. E. (2007) · Toxicology · doi:10.1016/j.tox.2007.03.007 · Cited by 181 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundNatural Medicines Comprehensive Database
Hsu, P. P. (2002) · Journal of the Medical Library Association JMLA · Cited by 179
Unger, M., & Frank, A. (2004) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1621 · Cited by 164 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundGanzera, M., Schneider, P., & Stuppner, H. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.095 · Cited by 151 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundZhang, C., Wang, S., Zhang, Y., Chen, J. P., & Liang, X. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.01.033 · Cited by 147 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundPotential of chemotherapy?herb interactions in adult cancer patients
McCune, J. S., Hatfield, A. J., Blackburn, A. A. R., Leith, P. O., Livingston, R. B., & Ellis, G. K. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0598-1 · Cited by 138 · cited 1×
“Greater than 85% of patients have reportedly admitted they would discontinue the use of herbal agents if a potentially harmful herb-drug interaction was suspected.(9) Much has been published regarding the potential for interactions between herbal products and conventional drugs, especially in the field of oncology.”
BackgroundMalati, C. Y., Robertson, S. M. C., Hunt, J. D., Chairez, C. L., Alfaro, R. M., Kovacs, J. A., & Penzak, S. R. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011407194 · Cited by 137 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundSen, G. S., Mohanty, S., Hossain, D. M. S., Bhattacharyya, S., Banerjee, S., Chakraborty, J., Saha, S., Ray, P., Bhattacharjee, P., Mandal, D. P., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.262295 · Cited by 123 · cited 1×
“These included herb-drug interactions, toxic effects of the herbal components, and alterations in the response of cancer cells to chemotherapy either through synergy or increased chemosensitivity.(96) Changes to the CYP, P-glycoprotein, or other metabolic pathways can either reduce the bioavailabilty of drugs (with de…”
BackgroundUse of Complementary and Alternative Medicine by Patients with Cancer in Saudi Arabia
Jazieh, A. R., Sudairy, R. A., Abulkhair, O. A. M., Alaskar, A. S., Safi, F. A., Sheblaq, N. R., Young, S. M., Issa, M., & Tamim, H. (2012) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0266 · Cited by 121 · cited 1×
“MATERIALS AND METHODS Background Review of the Literature An in-depth review focusing on CTM and herbal medicine use in cancer care among Middle Eastern patients was performed.(29,30) The implications on physician-patient communication were examined as well.”
BackgroundImatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity
Bilgi, N., Bell, K., Ananthakrishnan, A. N., & Atallah, E. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m715 · Cited by 118 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundGoey, A. K. L., Mooiman, K. D., Beijnen, J. H., Schellens, J. H. M., & Meijerman, I. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.008 · Cited by 110 · cited 1×
“Clinical research has revealed several directly toxic effects of herbal products,(20,21) as well as alterations in the pharmacokinetics of anticancer drugs,(22) although these findings are often contradictory as well.(23) The conflicting findings with regard to herb-drug interactions have precluded the development of…”
ResultAllman, M. A., Pena, M. M., & Pang, D. (1995) · PubMed · Cited by 107
Pharmacokinetic drug interactions involvingGinkgo biloba
Unger, M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.815200 · Cited by 107 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundEtheridge, A., Black, S., Patel, P., So, J., & Mathews, J. (2007) · Planta Medica · doi:10.1055/s-2007-981550 · Cited by 102 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
Kapadia, G. J., Rao, G. S., Ramachandran, C., Iida, A., Suzuki, N., & Tokuda, H. (2013) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2013-0007 · Cited by 100 · cited 1×
“The research has focused primarily on the effects of herbal components on the induction(10) and bioavailability of chemotherapy agents,(11) and is almost exclusively preclinical, in which cancer cell lines and animal models are exposed to combinations of herbal products and chemotherapeutic agents.(12,13) The potentia…”
BackgroundAntiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway
Son, D. J., Cho, M., Jin, Y.-R., Kim, S.-Y., Park, Y.-H., Lee, S., Akiba, S., Sato, T., & Yun, Y. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.12.004 · Cited by 95 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundYue, G. G., Cheng, S.-W., Yu, H., Xu, Z., Lee, J. K. M., Hon, P., Lee, M. Y. H., Kennelly, E. J., Deng, G. E., Yeung, K. S., et al. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2011.1845 · Cited by 95 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundGe, J., Tan, B., Chen, Y., Yang, L., Peng, X., Li, H.-Z., Lin, H., Zhao, Y. W., Wei, M., Cheng, K., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0737-3 · Cited by 92
Endale, M., Lee, W., Kamruzzaman, S., Kim, S., Park, J., Park, M., Park, T., Park, H., Cho, J., & Rhee, M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01967.x · Cited by 90 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundEfficacy and Safety of Mistletoe Preparations (Viscum album) for Patients with Cancer Diseases
Melzer, J., Iten, F., Hostanska, K., & Saller, R. (2009) · Complementary Medicine Research · doi:10.1159/000226249 · Cited by 89
Effect of onion and ginger consumption on platelet thromboxane production in humans
Srivastava, K. C. (1989) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(89)90122-1 · Cited by 86 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundPhytoestrogens after breast cancer.
This, P., de la Rochefordi�re, A., Clough, K. B., Fourquet, A., Magdelénat, H., & Breast Cancer Group of the Institut Curie (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080129 · Cited by 82 · cited 2×
“The inhibition of boronic acid–based proteasome inhibitors (eg, bortezomib)(51) or the transport of irinotecan and its metabolite, SN-38, can increase biliary removal with an increase in the half-life of the drug(52); a reduction in organic anion transporting polypeptides can increase the absorption of chemotherapy ag…”
BackgroundChen, P., Li, J., Jiang, H., Lan, T., & Chen, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2996-4 · Cited by 79 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundUnjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
Binkhorst, L., Mathijssen, R. H. J., van Herk‐Sukel, M. P. P., Bannink, M., Jager, A., Wiemer, E. A. C., & van Gelder, T. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2585-z · Cited by 78 · cited 1×
“An example of this is the interaction between tamoxifen and CYP-2D6 inhibitors such as selective serotonin reuptake inhibitors, which are used for the treatment of depression and hot flashes.(97) The use of such conventional drugs in conjunction with anticancer agents can also lead to reduced efficacy and increased to…”
BackgroundShin, S., & Choi, J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832d6834 · Cited by 77 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundWeissenstein, U., Kunz, M., Urech, K., & Baumgartner, S. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-6 · Cited by 75 · cited 1×
“The findings of this research are often contradictory, demonstrating either antagonistic effects,(16) additive effects,(17) synergy,(18) or no interaction whatsoever.(19) Clinical research has revealed several directly toxic effects of herbal products,(20,21) as well as alterations in the pharmacokinetics of anticance…”
Jia, W. W.-G., Bu, X., Philips, D., Yan, H., Liu, G., Chen, X., Bush, J., & Li, G. (2004) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-049 · Cited by 74 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundDietary Supplement Use in Cancer Care: Help or Harm
Hardy, M. L. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.04.012 · Cited by 73
Gupta, D., Lis, C. G., Birdsall, T. C., & Grutsch, J. F. (2005) · Supportive Care in Cancer · doi:10.1007/s00520-005-0820-9 · Cited by 70 · cited 1×
“As a result, many patients are seeking advice from family members, friends, or nonconventional medical practitioners.(6,7)Nevertheless, many patients expect conventional HCPs to provide up-to-date information and guidance on CTM treatments, including herbal medicine, as part of the medical consultation.”
BackgroundEffect of Chinese herbs on CYP3A4 activity and expression in vitro
Lau, C., Mooiman, K. D., Maas-Bakker, R. F., Beijnen, J. H., Schellens, J. H. M., & Meijerman, I. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.07.014 · Cited by 59 · cited 1×
“The potential for herb-drug interactions is attributed primarily to the drug-metabolizing enzyme cytochrome P450 (CYP450) system, of which CYP3A4 is the most predominant.(14) Other factors such as the transporter P-glycoprotein have been examined as well.”
BackgroundAttitude of employees of a university clinic to complementary and alternative medicine in oncology
Trimborn, A., Senf, B., Muenstedt, K., Büntzel, J., Micke, O., Mücke, R., Prott, F. J., Wicker, S., & Hübner, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt299 · Cited by 56
Ben‐Arye, E., Ali-Shtayeh, M. S., Nejmi, M., Schiff, E., Hassan, E., Mutafoğlu, K., Afifi‐Yazar, F. Ü., Jamous, R. M., Lev, E., & Silbermman, M. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1121-0 · Cited by 53 · cited 1×
“The Middle East is a region with a high affinity for CTM, including the use of herbal medicines, which has been reported for >60% of patients receiving adjuvant or palliative care.(27) We found that Middle Eastern oncology HCPs have a generally positive attitude toward the integration of CTM in supportive cancer care.”
BackgroundSelf-citationIn vitro Inhibition of Human CYP1A2, CYP2D6, and CYP3A4 by Six Herbs Commonly Used in Pregnancy
Langhammer, A. J., & Nilsen, O. G. (2013) · Phytotherapy Research · doi:10.1002/ptr.5037 · Cited by 52 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundSilibinin reverses drug resistance in human small-cell lung carcinoma cells
Sadava, D., & Kane, S. E. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.017 · Cited by 50 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundLin, L.-C., Wang, M.-N., & Tsai, T. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.033 · Cited by 48 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundÖzkol, H., Musa, D., Tülüce, Y., & Koyuncu, İ. (2011) · Drug and Chemical Toxicology · doi:10.3109/01480545.2011.598531 · Cited by 45 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundProbable Etoposide Interaction withEchinacea
Bossaer, J. B., & Odle, B. L. (2012) · Journal of Dietary Supplements · doi:10.3109/19390211.2012.682643 · Cited by 45
Antagonism between curcumin and the topoisomerase II inhibitor etoposide
Saleh, E., El‐Awady, R., Eissa, N. A., & Abdel‐Rahman, W. M. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21078 · Cited by 41 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundBen‐Arye, E., Attias, S., Tadmor, T., & Schiff, E. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.487622 · Cited by 40
Self-citationGinsenoside Metabolites Inhibit P-Glycoprotein In Vitro and In Situ Using Three Absorption Models
Li, N., Wang, D., Ge, G., Wang, X., Liu, Y., & Yang, L. (2014) · Planta Medica · doi:10.1055/s-0033-1360334 · Cited by 40 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundFlaxseed oil–trastuzumab interaction in breast cancer
Mason, J. K., Chen, J., & Thompson, L. U. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.05.052 · Cited by 38 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundReversal effect of Ganoderma lucidum polysaccharide on multidrug resistance in K562/ADM cell line
Li, W., ZHANG, B.-D., Ran, W. E. I., Liu, J., & Zhi-bin, L. I. N. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00776.x · Cited by 38 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundKim, C.-S., Choi, S.-J., Park, C.-Y., Li, C., & Choi, J. (2010) · PubMed · Cited by 37
Zheng, L., Lü, Y., Cao, X., Huang, Y., Liu, Y., Tang, L. J., Liao, S., Wang, A., Li, Y., Lan, Y., et al. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.10.031 · Cited by 37 · cited 2×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundTraditional Chinese Medicine Use among Chinese Immigrant Cancer Patients
Leng, J. C. F., & Gany, F. M. (2013) · Journal of Cancer Education · doi:10.1007/s13187-013-0542-5 · Cited by 36 · cited 1×
“Greater than 35% of patients with cancer in the United States report using herbal medicine during chemotherapy, with this rate exceeding 50% in developing countries.(1,2) Between 20% and 70% of patients using complementary and traditional medicine (CTM), including herbal agents, are often reluctant to disclose this pr…”
BackgroundThe prevalence of usage of herbal medicines among cancer patients.
Tuna, S., Dızdar, Ö., & Calis, M. (2013) · PubMed · Cited by 33
Use of complementary medications among older adults with cancer
Maggiore, R. J., Gross, C. P., Togawa, K., Tew, W. P., Mohile, S. G., Owusu, C., Klepin, H. D., Lichtman, S. M., Gajra, A., Ramani, R., et al. (2012) · Cancer · doi:10.1002/cncr.27427 · Cited by 32
Waters, N. J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12563 · Cited by 31 · cited 1×
“The use of such conventional drugs in conjunction with anticancer agents can also lead to reduced efficacy and increased toxicity.(98) The potential for drug-drug interactions should be addressed in clinical practice with the same rigor and thoroughness asis required when investigating herb-drug interactions.”
BackgroundChen, J.-L., Wang, J., Tsai, Y., Lin, Y.-H., Tseng, L., Chang, W.-C., King, K.-L., Chen, W.-S., Chiu, J., & Shyr, Y. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31827b2240 · Cited by 27
Ben‐Arye, E., Hamadeh, A. M. A., Schiff, E., Jamous, R. M., Dagash, J., Jamous, R. M., Agbarya, A., Bar‐Sela, G., Massalha, E., Silbermann, M., et al. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.10.006 · Cited by 25 · cited 3×
“This questionnaire was designed based on insights gleaned from an HCP focus group, as well as from a previous validated patient-oriented questionnaire that had been administered to patients with cancer in Israel and the Palestinian Authority.34,35 The use of CTM was based solely on the reports of oncology HCPs and not…”
MethodSelf-citationThe role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin.
Rastegar, H., Ashtiani, H. A., Anjarani, S., Bokaee, S., Khaki, A., & Javadi, L. (2013) · PubMed · Cited by 24
Vardy, J. L., Dhillon, H. M., Clarke, S. J., Olesen, I. H., Leslie, F. V. C., Warby, A., Beith, J. M., Sullivan, A., Hamilton, A. L., Beale, P. J., et al. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-126 · Cited by 21
Alcohol and polyphenolic grape extract inhibit platelet adhesion in flowing blood
de Lange, D. W., Scholman, W. L. G., Kraaijenhagen, R. J., Akkerman, J. N., & van de Wiel, A. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01432.x · Cited by 20 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundCommunicating with Patients about the Use of Complementary and Integrative Medicine in Cancer Care
Frenkel, M. A., & Ben‐Arye, E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-183-3_4 · Cited by 13 · cited 1×
“The implications on physician-patient communication were examined as well.(31,32)Preclinical and clinical research findings (English language) were searched using 4 databases (PubMed, Micromedex, AltMedDex, and The Comprehensive Natural Database) published between January 2010 and March 2015.”
BackgroundSelf-citationInhibition of Paclitaxel Metabolism In Vitro in Human Hepatocytes byGinkgo bilobaPreparations
Etheridge, A. S., Kroll, D. J., & Mathews, J. M. (2009) · Journal of Dietary Supplements · doi:10.1080/19390210902861817 · Cited by 12 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
BackgroundAlmog, L., Lev, E., Schiff, E., Linn, S., & Ben‐Arye, E. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2261-9 · Cited by 12 · cited 2×
“Earlier research concerning the role of HCPs in prescribing herbal medicine to their patients was conducted in an integrative setting in which a CTM-trained physician consulted patients on this practice.(4) In the overwhelming majority of cases, patients were found to have initiated the use of herbal products on their…”
BackgroundSelf-citationAltan, E., Bıtık, B., Kalpakçı, Y., Doğan, E., & Altundağ, K. (2009) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2008.0459 · Cited by 8 · cited 1×
“9%) (Table 3).(37-93) These were grouped according to 3 predominant themes: 1) potentially harmful herb-drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.”
Background(1996) · doi:10.1002/(sici)1099-1026(199611)11:6<373::aid-ffj628>3.0.co;2-5
Cited by
Targeting Drug Chemo-Resistance in Cancer Using Natural Products
Talib, W. H., Alsayed, A. R., Barakat, M., Abu-Taha, M. I., & Mahmod, A. I. (2021) · Biomedicines · doi:10.3390/biomedicines9101353 · Cited by 231
Metadata
- Authors
- Ben‐Arye, E., Samuels, N., Goldstein, L. H., Mutafoglu, K., Omran, S., Schiff, E., Charalambous, H., Dweikat, T., Ghrayeb, I., Bar‐Sela, G., Turker, I., Hassan, A., Hassan, E., Saad, B., Nimri, O., Kebudi, R., & Silbermann, M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2015-11-24
- Volume
- 122
- Issue
- 4
- Pages
- 598-610
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2178767900
- Cited by
- 158
- References
- 79
- FWCI
- 17.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.